易明医药（002826）8月19日主力资金净流入7824.78万元

Group 1 - The core viewpoint of the news highlights the financial performance and stock activity of Yiming Pharmaceutical (002826) as of August 19, 2025, with a closing price of 24.39 yuan, reflecting a slight increase of 0.12% [1] - The company reported a total operating revenue of 311 million yuan for the first half of 2025, representing a year-on-year decrease of 11.52%, while the net profit attributable to shareholders was 37.56 million yuan, down 5.27% year-on-year [1] - The company’s non-recurring net profit showed significant growth, reaching 25.02 million yuan, which is an increase of 102.33% compared to the previous year [1] Group 2 - The company has a current ratio of 2.688 and a quick ratio of 2.474, indicating strong liquidity, with a debt-to-asset ratio of 23.32% [1] - Yiming Pharmaceutical has made investments in 6 companies and participated in 10 bidding projects, showcasing its active engagement in the market [2] - The company holds 11 trademark registrations and 16 patents, along with 15 administrative licenses, reflecting its commitment to intellectual property and regulatory compliance [2]